Abstract
129P Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1016/j.iotech.2023.100601
Copy DOIJournal: Immuno-Oncology and Technology | Publication Date: Dec 1, 2023 |
129P Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score
Join us for a 30 min session where you can share your feedback and ask us any queries you have